ProMIS Neurosciences Inc. (PMN)

NASDAQ: PMN · IEX Real-Time Price · USD
5.87
-0.07 (-1.18%)
Aug 16, 2022 11:18 AM EDT - Market open
-1.18%
Market Cap 42.24M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 7.20M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 865
Open 5.91
Previous Close 5.94
Day's Range 5.87 - 5.87
52-Week Range 5.42 - 9.80
Beta 1.13
Analysts Buy
Price Target 22.31 (+280.1%)
Earnings Date Aug 11, 2022

About PMN

ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in A... [Read more...]

Industry Biotechnology
Founded 2004
CEO Elliot Goldstein
Employees 5
Stock Exchange NASDAQ
Ticker Symbol PMN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for PMN stock is "Buy." The 12-month stock price forecast is 22.31, which is an increase of 280.07% from the latest price.

Price Target
$22.31
(280.07% upside)
Analyst Consensus: Buy
Stock Forecasts

News

ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 15, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the d...

ProMIS Neurosciences Presents at 2022 Alzheimer's Association International Conference

Poster presentation of study highlighting oligomer selectivity of PMN310 compared to that of other amyloid-beta-directed antibodies Poster presentation of study highlighting oligomer selectivity of PMN3...

ProMIS Neurosciences to Present at 2022 Alzheimer's Association International Conference

Poster presentation of study comparing oligomer selectivity of PMN310 to that of other amyloid-beta-directed antibodies Poster presentation of study comparing oligomer selectivity of PMN310 to that of o...

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol “PMN”

TORONTO, Ontario and CAMBRIDGE, Massachusetts, July 08, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (TSX: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the di...

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

TORONTO, Ontario and CAMBRIDGE, MA, June 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential t...

ProMIS Neurosciences Announces Debt Amendment and Conversion

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the d...

ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the ...

ProMIS Neurosciences Announces Authorization of Series 1 Preferred Shares

TORONTO, Ontario and CAMBRIDGE, Massachusetts, June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the d...

ProMIS Neurosciences presents at the 2022 Neuro4D International Conference

TORONTO, Ontario and CAMBRIDGE, MA, May 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutic...

CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no oth...

ProMIS Neurosciences Announces First Quarter 2022 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the d...

ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce the Annual and...

Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at t...

TORONTO, Ontario, May 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”) is pleased to announce that leading independent proxy advisory firms, I...

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

TORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of potential...

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

Brings decades of experience in Alzheimer's research at large pharma and biotech Brings decades of experience in Alzheimer's research at large pharma and biotech

Argus Research Initiates Equity Report Coverage on ProMIS Neurosciences, Inc. (TSX:PMN & OTCQB: ARFXF)

NEW YORK , April 18, 2022 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN) Click here  to view F...

ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting

TORONTO, Ontario and CAMBRIDGE, MA, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeut...

ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, April 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “ Corporation ”), is pleased to announce it has mai...

ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit

TORONTO, Ontario and CAMBRIDGE, MA , March 24, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeu...

ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer's Vaccine at the 2022 International A...

Customized vaccine selectively targets toxic amyloid-beta oligomers Customized vaccine selectively targets toxic amyloid-beta oligomers

ProMIS Neurosciences Announces Fiscal Year 2021 Results

TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on th...

ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM...

Optimizing vaccine design for Alzheimer's disease Optimizing vaccine design for Alzheimer's disease

ProMIS Neurosciences' PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer's disease

Transgenic mouse model reflects latest scientific understanding of disease – toxic oligomers of amyloid create cognitive deficit Transgenic mouse model reflects latest scientific understanding of diseas...

ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Adviso...

TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibo...

ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advis...

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibod...